Phase II RCT of metformin examined aging markers in middle-aged and elderly adults
A Phase II randomized controlled trial investigated whether oral metformin could slow aging processes in middle-aged and elderly people. The study aimed to identify sensitive markers of aging and develop frameworks for anti-aging interventions, though specific findings, sample size, and effect sizes were not reported in the available information.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Mar 21, 2025 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Middle-aged and elderly males
- Primary outcome
- Geroprotective effect of metformin; aging process mitigation
- Effect size
- —
- Significance
- Not reported
- Journal
- Xuanwu Hospital, Beijing
- Published
- Mar 21, 2025
Sources
Primary source
- Xuanwu Hospital, Beijing ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.